Your browser doesn't support javascript.
loading
The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
Weidenauer, Katharina; Schmidt, Christina; Rohde, Christian; Pauli, Cornelius; Blank, Maximilian F; Heid, Daniel; Waclawiczek, Alexander; Corbacioglu, Anika; Göllner, Stefanie; Lotze, Michelle; Vierbaum, Lisa; Renders, Simon; Krijgsveld, Jeroen; Raffel, Simon; Sauer, Tim; Trumpp, Andreas; Pabst, Caroline; Müller-Tidow, Carsten; Janssen, Maike.
Afiliação
  • Weidenauer K; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Schmidt C; University of Heidelberg Medical Faculty, Heidelberg, Germany.
  • Rohde C; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Pauli C; University of Heidelberg Medical Faculty, Heidelberg, Germany.
  • Blank MF; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Heid D; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Waclawiczek A; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Corbacioglu A; Division of Mechanisms Regulating Gene Expression, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Göllner S; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Lotze M; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Vierbaum L; Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Renders S; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Krijgsveld J; Molecular Medicine Partnership Unit (MMPU), University of Heidelberg and European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
  • Raffel S; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
  • Sauer T; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
  • Trumpp A; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Pabst C; University of Heidelberg Medical Faculty, Heidelberg, Germany.
  • Müller-Tidow C; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Janssen M; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Leukemia ; 37(8): 1611-1625, 2023 08.
Article em En | MEDLINE | ID: mdl-37414921
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda / Resistencia a Medicamentos Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda / Resistencia a Medicamentos Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article